313 related articles for article (PubMed ID: 20155263)
21. Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.
Saki M; Toulany M; Sihver W; Zenker M; Heldt JM; Mosch B; Pietzsch HJ; Baumann M; Steinbach J; Rodemann HP
Strahlenther Onkol; 2012 Sep; 188(9):823-32. PubMed ID: 22875052
[TBL] [Abstract][Full Text] [Related]
22. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.
Milenic DE; Wong KJ; Baidoo KE; Nayak TK; Regino CA; Garmestani K; Brechbiel MW
MAbs; 2010; 2(5):550-64. PubMed ID: 20716957
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
24. A novel bifunctional maleimido CHX-A'' chelator for conjugation to thiol-containing biomolecules.
Xu H; Baidoo KE; Wong KJ; Brechbiel MW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2679-83. PubMed ID: 18359632
[TBL] [Abstract][Full Text] [Related]
25. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
[TBL] [Abstract][Full Text] [Related]
26. Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide.
Clifford T; Boswell CA; Biddlecombe GB; Lewis JS; Brechbiel MW
J Med Chem; 2006 Jul; 49(14):4297-304. PubMed ID: 16821789
[TBL] [Abstract][Full Text] [Related]
27. Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH.
Wei L; Zhang X; Gallazzi F; Miao Y; Jin X; Brechbiel MW; Xu H; Clifford T; Welch MJ; Lewis JS; Quinn TP
Nucl Med Biol; 2009 May; 36(4):345-54. PubMed ID: 19423001
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer.
Parry R; Schneider D; Hudson D; Parkes D; Xuan JA; Newton A; Toy P; Lin R; Harkins R; Alicke B; Biroc S; Kretschmer PJ; Halks-Miller M; Klocker H; Zhu Y; Larsen B; Cobb RR; Bringmann P; Roth G; Lewis JS; Dinter H; Parry G
Cancer Res; 2005 Sep; 65(18):8397-405. PubMed ID: 16166318
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.
Milenic DE; Wong KJ; Baidoo KE; Ray GL; Garmestani K; Williams M; Brechbiel MW
Cancer Biother Radiopharm; 2008 Oct; 23(5):619-31. PubMed ID: 18999934
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Characterization of the
Striese F; Neuber C; Gräßel S; Arndt C; Ullrich M; Steinbach J; Pietzsch J; Bergmann R; Pietzsch HJ; Sihver W; Frenz M; Feldmann A; Bachmann MP
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298374
[TBL] [Abstract][Full Text] [Related]
31. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.
Cai W; Chen K; He L; Cao Q; Koong A; Chen X
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214
[TBL] [Abstract][Full Text] [Related]
32. Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a.
Burvenich IJ; Parakh S; Gan HK; Lee FT; Guo N; Rigopoulos A; Lee ST; Gong S; O'Keefe GJ; Tochon-Danguy H; Kotsuma M; Hasegawa J; Senaldi G; Scott AM
J Nucl Med; 2016 Jun; 57(6):974-80. PubMed ID: 26940768
[TBL] [Abstract][Full Text] [Related]
33. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
34. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
Roselli M; Milenic DE; Brechbiel MW; Mirzadeh S; Pippin CG; Gansow OA; Colcher D; Schlom J
Cancer Biother Radiopharm; 1999 Jun; 14(3):209-20. PubMed ID: 10850305
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.
Kobayashi H; Wu C; Yoo TM; Sun BF; Drumm D; Pastan I; Paik CH; Gansow OA; Carrasquillo JA; Brechbiel MW
J Nucl Med; 1998 May; 39(5):829-36. PubMed ID: 9591585
[TBL] [Abstract][Full Text] [Related]
36. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Hens M; Vaidyanathan G; Zhao XG; Bigner DD; Zalutsky MR
Nucl Med Biol; 2010 Oct; 37(7):741-50. PubMed ID: 20870149
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers.
Kameswaran M; Pandey U; Gamre N; Vimalnath KV; Sarma HD; Dash A
Appl Radiat Isot; 2016 Aug; 114():196-201. PubMed ID: 27258216
[TBL] [Abstract][Full Text] [Related]
38. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.
Sadri K; Ren Q; Zhang K; Paudyal B; Devadhas D; Rodeck U; Thakur M
Nucl Med Commun; 2011 Jul; 32(7):563-9. PubMed ID: 21572364
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
